Masaya Miyamoto

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

Ryohei Katayama, Bo Gong, Noriko Togashi et al. · Nature Communications · 2019 · 141 citations · Full text

Medicine, Oncology, Pharmacology +15

REG4 is a transcriptional target of GATA6 and is essential for colorectal tumorigenesis

Yoshihiro Kawasaki, Kosuke Matsumura, Masaya Miyamoto et al. · Scientific Reports · 2015 · 51 citations · Full text

Medicine, Molecular Biology, Oncology +14

The miR-1-NOTCH3-Asef Pathway Is Important for Colorectal Tumor Cell Migration

Shiori Furukawa, Yoshihiro Kawasaki, Masaya Miyamoto et al. · PLoS ONE · 2013 · 48 citations · Full text

Medicine, Molecular Biology, Oncology +17

The novel lncRNA CALIC upregulates AXL to promote colon cancer metastasis

Yoshihiro Kawasaki, Masaya Miyamoto, Takeaki Oda et al. · EMBO Reports · 2019 · 38 citations · Full text

Medicine, Molecular Biology, Oncology +12

Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models

Genzui Setsu, Megumi Goto, Kentaro Ito et al. · European Journal of Pharmacology · 2023 · 19 citations

Medicine, Medicinal Chemistry, Pharmacology +13